New funding for life science projects
14 Jul 2017 by Evoluted New Media
Lab282, a partnership between Oxford University and Evotec, a drug discovery company, has announced funding for five new projects.
The new projects, in addition to financial support, will also receive ongoing support from Oxford University Innovation (OUI), a research commercialisation company and access to Evotec’s industry knowledge. This will help the projects become successful spin-out companies.
Dr Thomas Hanke, Evotec’s Lab282 Expert-in-Residence, said: “Our BRIDGE model is bringing together world-class research, global life sciences leadership and expertise, and an investor which understands the sector and is bold enough to back it all the way. We’re already beginning to see this partnership bloom, and everyone involved in the partnership knows that this is just the start.”
The concepts supported by the Lab282 are:
- A novel treatment concept to inhibit chemotherapy-induced nerve damage
- A potential new class of antibiotics
- A new target for the treatment of heart failure
- Therapeutics for chronic inflammatory disorders of the digestive system
- Potential relief from rheumatoid arthritis
